Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

390.00DKK
21 Jun 2017
Change (% chg)

kr.7.00 (+1.83%)
Prev Close
kr.383.00
Open
kr.382.50
Day's High
kr.390.00
Day's Low
kr.382.00
Volume
304,806
Avg. Vol
191,468
52-wk High
kr.390.00
52-wk Low
kr.197.00

Select another date:

Fri, Jun 16 2017

BRIEF-Bavarian Nordic announces notification of RFP for freeze-dried imvamune

* REG-BAVARIAN NORDIC ANNOUNCES NOTIFICATION OF REQUEST FOR PROPOSAL (RFP ) FOR FREEZE-DRIED IMVAMUNE

BRIEF-Bavarian Nordic launches share buy-back program to hedge incentive scheme obligations

* REG-BAVARIAN NORDIC LAUNCHES SHARE BUY-BACK PROGRAM TO HEDGE INCENTIVE SCHEME OBLIGATIONS

BRIEF-Bavarian Nordic appoints Dr. Tommi Kainu as Chief Business Officer, effective july 1

* APPOINTS DR. TOMMI KAINU AS CHIEF BUSINESS OFFICER, EFFECTIVE JULY 1 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Bavarian nordic Q1 EBIT loss narrows to DKK 3.1 million

* Q1 EBIT LOSS 3.1 DKK MILLION VERSUS LOSS DKK 152.7 MILLION YEAR AGO

BRIEF-Valneva signs new EB66 commercial license with Bavarian Nordic

* Announces signing of a new EB66 commercial license with Bavarian Nordic

BRIEF-Bavarian Nordic FY EBIT rises to DKK 33.0 million

* FY revenue 1.01 billion Danish crowns ($145 million) versus 1.02 billion crowns year ago

BRIEF-Bavarian Nordic: collaboration to evaluate CV301 and Tecentriq in bladder cancer

* Announces collaboration to evaluate CV301 and tecentriq in bladder cancer

BRIEF-Bavarian Nordic announces 6-mth follow-up data from phase 1 trial of MVA-BN RSV

* Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

Select another date:

More From Around the Web